Unique ADC Strategy Targets Leukemia Antibodies attack a cancer cell or virus April 19, 2021 Taking advantage of the extreme sensitivity for monoclonal antibodies while simultaneously coupling the immunoprotein to a cytotoxic payload is the foundation of antibody-drug conjugates (ADCs). However, developing the antibody portion of ADCs to target cell surface proteins specific to various cancer cells is challenging. Yet now, a group of Japanese researchers at the Tokyo Medical and Dental University (TMDU) have recently developed an ingenious strategy against chronic myelomonocytic leukemia (CMML) wherein the ADC effectively blocked malignant cell proliferation at the source. Findings from the new study were published recently in